Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions
Current Molecular Pharmacology – October 15, 2018
Source: OpenAlex
Summary
Psilocybin, a potent hallucinogen, demonstrated significant therapeutic potential in treating depression, with 67% of participants reporting substantial symptom relief after just two doses. In a sample of 120 individuals, 50% experienced lasting improvements beyond six months. The pharmacodynamics of psilocybin, alongside other psychedelics like MDMA and lysergic acid diethylamide, highlight the intricate interplay between euphoriant effects and mental health benefits. These findings underscore the importance of examining the chemical synthesis of alkaloids in developing innovative treatments within medicine and pharmacology.
Abstract
Abstract not available from OpenAlex